Panacea Biotec Limited (PANACEABIO) AI Stock Analysis

• Market Cap: ₹25.01B
• Dividend Yield: N/A
• Average Volume (3M): 16.14K
• Price to Earnings (P/E): 217.9
• Beta (1Y): 1.64
• Revenue Growth: 11.80%
• EPS Growth: N/A
• Country: IN
• Employees: 1,936
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.66
• Shares Outstanding: 61,250,744
• 10 Day Avg. Volume: 13,371
• 30 Day Avg. Volume: 16,140
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹426.00
• Price Target Upside: 4.31% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ₹402.00 ▼(-1.57% Downside)

Panacea Biotec's overall stock score is primarily impacted by its financial performance challenges, including declining revenue and profitability, and negative cash flow. The technical analysis provides a mixed outlook, with some potential for upward momentum but overall neutral to bearish sentiment. The high P/E ratio indicates overvaluation, further weighing down the score.

Panacea Biotec Limited Business Overview & Revenue Model

Company Description

Panacea Biotec Limited, a biotechnology company, engages in the research and development, manufacture, and marketing of pharmaceuticals, vaccines, and biosimilars in India. It operates through Vaccines and Formulations segments. The company's product portfolio includes prescription products in various therapeutic areas, such as pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care; and vaccines for anthrax, dengue, Japanese encephalitis, and others. It also exports its products to over 30 countries worldwide, including the United States, Germany, the Russian Federation, Sri Lanka, the Philippines, etc. The company has a collaboration agreement with the Russian Direct Investment Fund for producing Covid-19 vaccine Sputnik-V; and the Coalition for Epidemic Preparedness Innovations and Translational Health Science and Technology Institute to develop vaccine candidates that could protect against SARS-Cov-2 variants and other Beta coronaviruses. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

How the Company Makes Money

Panacea Biotec generates revenue through the sale of its pharmaceutical products and vaccines, which are distributed in both domestic and international markets. The company's primary revenue streams include the manufacturing and sale of vaccines for diseases such as polio and tetanus, as well as pharmaceuticals used in therapies for organ transplantation, oncology, and diabetes management. Panacea Biotec also engages in partnerships and collaborations with global pharmaceutical companies to develop and commercialize various drug products. These strategic alliances and licensing agreements further contribute to its earnings, alongside government contracts and supply agreements for vaccines.

Panacea Biotec Limited Financial Statement Overview

Summary

Panacea Biotec faces significant financial challenges with declining revenue, negative profitability, and liquidity issues. Despite a strong equity position and effective leverage management, the company struggles with cash flow generation and operational difficulties.

Income Statement

Panacea Biotec's income statement shows mixed performance with declining revenue and profitability. The gross profit margin for 2025 is approximately 64.31%, indicating decent cost management. However, the company has been experiencing negative EBIT and net income, reflecting operational challenges. The net profit margin is negative due to consistent net losses, and revenue growth has stagnated, showing no growth from 2024 to 2025.

Balance Sheet

The balance sheet indicates a strong equity position with a debt-to-equity ratio of 0.03 in 2025, showing effective leverage management. However, the company has faced declining total assets and stockholders' equity over the years. The equity ratio stands at 64.73% in 2025, suggesting a stable financial structure, but the decline in assets could be a concern for future growth.

Cash Flow

Panacea Biotec's cash flow statement reveals liquidity challenges, with negative operating cash flow and free cash flow in 2025. The company is struggling to generate cash from operations, reflected in the negative operating cash flow to net income ratio. The free cash flow to net income ratio is also negative, indicating a need for improvement in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	5.63B	5.59B	5.59B	4.60B	6.59B	6.18B
Gross Profit	2.72B	3.60B	3.29B	2.07B	3.42B	4.13B
EBITDA	288.30M	307.40M	415.37M	563.65M	16.74B	865.18M
Net Income	-81.43M	-83.70M	-11.73M	-332.37M	10.78B	-1.48B
Balance Sheet
Total Assets	0.00	12.90B	12.41B	12.71B	17.59B	11.78B
Cash, Cash Equivalents and Short-Term Investments	1.77B	1.79B	1.56B	2.13B	5.52B	954.44M
Total Debt	0.00	222.10M	209.90M	202.19M	341.55M	8.20B
Total Liabilities	-8.29B	4.59B	4.02B	4.31B	8.85B	14.09B
Stockholders Equity	8.29B	8.35B	8.42B	8.44B	8.77B	-2.29B
Cash Flow
Free Cash Flow	0.00	-776.80M	-778.18M	-4.63B	-1.21B	850.01M
Operating Cash Flow	0.00	-273.70M	-1.00M	-4.22B	-1.08B	1.07B
Investing Cash Flow	0.00	649.80M	102.27M	4.30B	12.83B	-476.79M
Financing Cash Flow	0.00	-26.60M	-28.08M	-183.73M	-11.76B	-471.10M

Panacea Biotec Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 408.40
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PANACEABIO, the sentiment is Neutral. The current price of 408.4 is below the 20-day moving average (MA) of 419.35, below the 50-day MA of 418.18, and below the 200-day MA of 432.23, indicating a neutral trend. The MACD of 6.62 indicates Negative momentum. The RSI at 51.52 is Neutral, neither overbought nor oversold. The STOCH value of 58.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:PANACEABIO.

Panacea Biotec Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	649.10B	19.15	10.68%	0.36%	7.76%	-2.84%
ALKEM	72 Outperform	657.13B	28.96	18.07%	0.82%	4.49%	11.22%
GLAXO	66 Neutral	467.75B	48.81	47.54%	1.95%	6.65%	48.47%
IPCALAB	66 Neutral	354.70B	46.59	10.62%	0.29%	11.49%	35.00%
GLENMARK	54 Neutral	568.45B	78.05	11.83%	0.12%	10.99%	0.00%
PANACEABIO	47 Neutral	₹25.01B	217.89		―	11.80%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Panacea Biotec Limited Corporate Events

Panacea Biotec Announces 41st AGM Details and Compliance Measures

Panacea Biotec Limited announced the publication of a newspaper notice regarding its 41st Annual General Meeting, including details about the cut-off date and remote e-voting. This announcement is part of the company’s compliance with SEBI regulations, ensuring transparency and shareholder engagement in its governance processes.

Panacea Biotec Releases Q1 2025 Financial Results

Panacea Biotec Limited has published its unaudited standalone and consolidated financial results for the quarter ending June 30, 2025, in compliance with SEBI regulations. The financial results were published in Business Standard and Desh Sewak newspapers, indicating the company’s commitment to transparency and regulatory compliance. This announcement may impact the company’s stakeholders by providing insights into its financial health and operational performance.